# Nephrotic Syndrome

Nephrotic syndrome requires rapid identification of thrombosis, acute kidney injury, infection, and an etiologic branch that determines biopsy, secondary-disease evaluation, supportive measures, and disease-specific immunosuppression.

**Clinical question:** How should clinicians triage, classify, and manage nephrotic syndrome while selecting cause-directed therapy?

Updated: 2026-08-21T01:47:48.754677+00:00

## What matters in practice
- Treat new nephrotic syndrome as a diagnostic syndrome: distinguish primary podocytopathy or membranous nephropathy from infection-, autoimmune-, drug-, malignancy-, genetic-, and amyloid-associated disease before choosing immunosuppression.[6][7][12]
- Prioritize evaluation for venous or arterial thrombosis; thromboembolic risk in nephrotic syndrome may reach 40% depending on severity and underlying cause.[16]
- In adults, membranous nephropathy is a major primary cause; hepatitis B or C, malignancy, systemic lupus erythematosus, and drugs including gold and penicillamine are important secondary branches.[7]
- For progressive primary membranous nephropathy with nephrotic syndrome and risk of progression, rituximab, cyclophosphamide plus glucocorticoids, and calcineurin inhibitor-based regimens are guideline-supported first-line options; regimen selection must account for renal pathology and treatment toxicity.[21]
- Rituximab is most useful for steroid-dependent nephrotic syndrome and may permit steroid reduction and calcineurin-inhibitor withdrawal; benefit is limited in calcineurin-inhibitor-refractory steroid-resistant disease, particularly FSGS.[4][14]

## Identify complications that change same-day management

Evaluate unstable or organ-threatening complications before pursuing definitive histology.

Obtain serum creatinine/eGFR, serum albumin, quantitative proteinuria, urinalysis with microscopy, blood pressure, weight, and medication exposure at presentation. Escalate urgently for rapidly worsening kidney function, oliguria, severe hypertension, pulmonary edema, suspected sepsis, or symptoms of pulmonary embolism, deep-vein thrombosis, renal-vein thrombosis, stroke, or acute limb ischemia. Nephrotic syndrome carries both venous and arterial thromboembolic risk; reported overall risk can be as high as 40%, varying with disease severity and etiology.[16]

Use the thrombotic presentation to direct imaging rather than screening indiscriminately: obtain compression ultrasonography for unilateral limb symptoms and chest imaging appropriate to suspected pulmonary embolism. A confirmed thrombotic event requires therapeutic anticoagulation; the unresolved decision is primary prophylaxis, for which evidence remains limited and risk-benefit assessment must weigh nephrotic severity, underlying disease, and bleeding risk.[16]

If edema is accompanied by dyspnea, hypoxemia, or pulmonary congestion, determine whether volume excess, pulmonary embolism, or cardiac amyloid is contributing. In suspected AL amyloidosis, renal involvement is defined by albuminuria of at least 0.5 g/24 h; cardiac staging incorporates cardiac biomarkers and has direct prognostic implications.[12]
- Send urine microscopy early: a bland sediment supports a podocytopathy or membranous pattern, whereas an active sediment should redirect evaluation toward inflammatory or immune-complex glomerular disease.
- Review nonsteroidal anti-inflammatory drugs, lithium, interferon exposure, gold, penicillamine, and recent infections; gold and penicillamine are recognized secondary causes of membranous nephropathy.[7]
- Do not attribute edema solely to hypoalbuminemia when acute dyspnea, pleuritic pain, focal neurologic deficits, or unilateral leg swelling suggests thrombosis.[16]

*Immediate complications and next diagnostic action in nephrotic syndrome.[12][16]*

| Clinical signal | Immediate test or action | Interpretation and next step |
| --- | --- | --- |
| Unilateral leg swelling or pain | Compression venous ultrasonography | Confirm or exclude deep-vein thrombosis; treat a confirmed event with therapeutic anticoagulation.[16] |
| Dyspnea, pleuritic pain, hypoxemia, or syncope | Pulmonary embolism evaluation with appropriate chest imaging | Nephrotic syndrome confers substantial thromboembolic risk; do not presume edema alone explains respiratory symptoms.[16] |
| Rapid creatinine rise or oliguria | Repeat creatinine/eGFR, urine microscopy, volume assessment, and renal imaging when obstruction or renal-vein thrombosis is plausible | Accelerate nephrology assessment and etiologic workup before empiric immunosuppression. |
| Proteinuria with systemic features suggesting amyloid | Quantify albuminuria; assess cardiac biomarkers and echocardiography when cardiac involvement is suspected | Albuminuria at least 0.5 g/24 h defines renal involvement in AL amyloidosis; cardiac involvement changes staging and treatment urgency.[12] |

## Use age, systemic context, and pathology to define the etiologic branch

The critical decision is whether proteinuria reflects a primary glomerular lesion or secondary systemic disease.

In children, minimal change disease is the leading cause of nephrotic syndrome; it also occurs in adults.[7][18] In an otherwise typical child, response to initial glucocorticoid therapy helps classify the course as steroid-sensitive, frequently relapsing, steroid-dependent, or steroid-resistant and determines the need for steroid-sparing treatment.[1][3][8]

In adults, assess specifically for membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis (FSGS), and systemic causes. Membranous nephropathy principally affects middle-aged and older adults and may be secondary to hepatitis B, hepatitis C, malignancy, systemic lupus erythematosus, or drugs such as gold and penicillamine.[7] A positive exposure or systemic branch should trigger targeted treatment of the associated disease rather than automatic classification as primary membranous nephropathy.

Evaluate for amyloidosis when nephrotic proteinuria coexists with a plasma-cell disorder, unexplained cardiomyopathy, neuropathy, hepatomegaly, or multisystem disease. For AL amyloidosis, renal staging uses eGFR 50 mL/min/1.73 m² or less and proteinuria 5 g/24 h or more: meeting neither threshold is stage I, either threshold stage II, and both stage III.[12]

Consider inherited basement-membrane disease when hematuria, hearing loss, ocular findings, or family history coexist with proteinuria. Alport syndrome can progress to FSGS histology through podocyte loss; males with X-linked disease and individuals with autosomal recessive disease may develop nephrotic-range proteinuria or nephrotic syndrome, whereas this is rare in heterozygous autosomal disease and should prompt assessment for an additional contributor.[10]
- Order hepatitis B and hepatitis C testing when membranous nephropathy is considered, because both infections are recognized secondary causes.[7]
- Perform a directed malignancy and systemic autoimmune assessment in adult membranous nephropathy rather than labeling disease idiopathic before secondary causes have been considered.[7]
- Use kidney biopsy to establish lesion pattern and to distinguish membranous nephropathy, minimal change disease, FSGS, amyloid, and secondary glomerular processes when clinical data do not establish a safe treatment path.[6]

### Pathology patterns that alter treatment

Minimal change disease and FSGS occupy a podocytopathy branch but have materially different treatment expectations. Rituximab can reduce relapses and glucocorticoid-sparing therapy in frequently relapsing or steroid-dependent minimal change disease, whereas response is substantially less favorable in steroid-resistant nephrotic syndrome after calcineurin-inhibitor failure, particularly FSGS.[4][14]

Membranous nephropathy requires explicit separation of secondary disease from progressive primary disease. Persistent nephrotic syndrome that fails to respond is associated with risk of progression to kidney failure, while mild-to-moderate proteinuria is generally associated with a more favorable prognosis.[21]
- Do not interpret an FSGS lesion as automatically primary: Alport syndrome and other genetic or secondary processes can produce FSGS through progressive podocyte injury.[10]
- In amyloid-associated nephrotic syndrome, stage renal and cardiac involvement because eGFR, proteinuria, and cardiac biomarkers are used for prognosis.[12]

*Etiologic branches that should change diagnostic testing and treatment selection.[7][10][12]*

| Branch | Discriminators | Next action |
| --- | --- | --- |
| Childhood steroid-sensitive podocytopathy | Childhood onset; minimal change disease is the leading cause of nephrotic syndrome in children.[7][18] | Classify glucocorticoid response and relapse pattern; reserve steroid-sparing strategies for complicated, frequent-relapse, or steroid-dependent disease.[1][3][8] |
| Primary or secondary membranous nephropathy | Middle-aged or older adult; test for hepatitis B, hepatitis C, malignancy, lupus, and exposure to gold or penicillamine.[7] | Treat identified secondary drivers and use biopsy plus clinical progression risk to guide immunosuppression.[6][21] |
| Steroid-resistant FSGS or related lesion | Steroid resistance, reduced response to rituximab after calcineurin-inhibitor failure, or hereditary features.[4][10] | Reassess for genetic and secondary causes; do not expect rituximab benefit comparable to steroid-dependent disease.[4] |
| AL amyloidosis | Multisystem phenotype; renal involvement with albuminuria at least 0.5 g/24 h.[12] | Stage kidney disease using eGFR 50 mL/min/1.73 m² and proteinuria 5 g/24 h; stage cardiac involvement with biomarkers.[12] |
| Alport syndrome | Familial hematuria or extrarenal phenotype; later biopsy may show FSGS.[10] | Confirm inherited disease and institute renin-angiotensin system blockade; ramipril target dosing is 6 mg/m²/day in the cited guideline.[10] |

## Reduce proteinuria and prevent nephrotic complications while definitive diagnosis proceeds

Supportive treatment runs in parallel with biopsy, secondary-cause testing, and disease-specific therapy.

Optimize blood pressure and antiproteinuric therapy with a maximally tolerated ACE inhibitor or angiotensin receptor blocker when not contraindicated. Renin-angiotensin system blockade is central supportive therapy across proteinuric glomerular disease, with the treatment goal of lowering proteinuria and controlling blood pressure.[10][11] Monitor creatinine, potassium, blood pressure, and volume status after initiation or dose escalation.

For Alport syndrome, the cited 2024 guideline identifies ramipril as the most extensively studied agent: start 1 to 2 mg/m²/day and titrate to a target maximum of 6 mg/m²/day.[10] This dose is disease-specific evidence and should not be extrapolated as a universal nephrotic-syndrome dosing rule.

Assess prophylactic anticoagulation separately from treatment-dose anticoagulation. Earlier KDIGO guidance recommended prophylaxis only in idiopathic membranous nephropathy, and the supporting evidence was acknowledged to be limited and low quality.[16] Use an individualized decision that incorporates membranous histology, nephrotic severity, prior thrombosis, immobility, and bleeding risk rather than applying a universal prophylaxis rule to all nephrotic presentations.

Reassess urine protein excretion, serum albumin, eGFR, blood pressure, weight, and treatment toxicity longitudinally. Persistent nephrotic syndrome despite therapy is a progression signal in primary membranous nephropathy and should prompt reassessment of adherence, secondary causes, histologic context, and the selected immunosuppressive regimen.[21]
- Use low-sodium dietary measures together with renin-angiotensin system blockade as part of proteinuria and blood-pressure management.[11]
- Avoid dual ACE inhibitor and ARB therapy; select one renin-angiotensin system blocker and titrate to tolerated dosing.
- Before immunosuppression, document infection risks and complete the secondary-cause evaluation relevant to the suspected lesion.

*Monitoring domains during supportive and immunosuppressive management.*

| Domain | What to follow | Decision triggered |
| --- | --- | --- |
| Proteinuria and albumin | Quantitative urine protein and serum albumin | Persistent nephrotic syndrome indicates continued disease activity and should trigger treatment reassessment in primary membranous nephropathy.[21] |
| Kidney function | Serum creatinine and eGFR | eGFR 50 mL/min/1.73 m² or less is a renal staging threshold in AL amyloidosis.[12] |
| Renin-angiotensin system blockade | Blood pressure, potassium, and creatinine after dose changes | Adjust or hold therapy for intolerance; aim for maximal tolerated blockade to lower proteinuria.[10][11] |
| Thrombotic risk | New respiratory, neurologic, abdominal, or unilateral limb symptoms | Investigate symptomatic venous or arterial thrombosis promptly; nephrotic syndrome may carry thromboembolic risk up to 40% in selected settings.[16] |

## Match immunosuppression to lesion and response phenotype

Do not use response patterns from one nephrotic lesion to predict efficacy in another.

In complicated childhood steroid-dependent nephrotic syndrome, rituximab is an effective long-term steroid-sparing option and can support withdrawal of calcineurin inhibitors.[3][4] In adult minimal change disease with frequently relapsing or steroid-dependent disease, available series and meta-analysis data show reduced relapses and reduced glucocorticoid-sparing immunosuppression after rituximab; reported response rates across studies ranged from 63% to 100%, but these data are largely nonrandomized and should not be generalized to steroid-resistant FSGS.[14]

For steroid-resistant nephrotic syndrome that has not responded to calcineurin inhibitors, counsel that rituximab efficacy is limited, especially with FSGS.[4] This pattern should prompt renewed scrutiny for genetic, adaptive, infectious, drug-associated, or inherited causes rather than serial empiric B-cell depletion.

For primary membranous nephropathy with nephrotic syndrome and risk of disease progression, guideline-recognized first-line approaches include rituximab, cyclophosphamide combined with glucocorticoids, and calcineurin inhibitor-based treatment.[21] Selection requires an explicit tradeoff: calcineurin inhibitors can reduce proteinuria and achieved higher remission-related outcomes than cyclophosphamide at 6 months in a meta-analysis, but differences were no longer significant by 12 months; cyclosporine did not improve renal function or provide durable benefit in an earlier progressive-disease trial.[15][22]

Reserve disease-specific therapy for amyloidosis and systemic autoimmune or infection-associated glomerular disease for the confirmed systemic diagnosis. In AL amyloidosis, renal stage and cardiac biomarker stage quantify organ involvement and should guide urgency and multidisciplinary hematology-nephrology treatment planning.[12]
- Steroid-dependent disease: consider rituximab when recurrent glucocorticoid toxicity or calcineurin-inhibitor dependence makes a steroid-sparing strategy necessary.[3][4][14]
- Calcineurin-inhibitor-refractory steroid-resistant FSGS: do not assume rituximab will produce the response seen in steroid-dependent nephrotic syndrome.[4]
- Progressive primary membranous nephropathy: choose among rituximab, cyclophosphamide plus glucocorticoids, and calcineurin inhibitor-based therapy based on progression risk, comorbidities, reproductive considerations, infection risk, and likelihood of treatment adherence.[21]

### Membranous nephropathy treatment tradeoffs

A network meta-analysis of 45 studies reported higher total-remission probabilities for several immunosuppressive regimens than nonimmunosuppressive therapy, including tacrolimus, cyclosporine, cyclophosphamide, mycophenolate mofetil, and rituximab; comparative rankings should be interpreted cautiously because the evidence base includes heterogeneous regimens and study designs.[2] In current practice, selection should prioritize guideline-supported regimens and patient-specific toxicity rather than using network ranking alone.
- Cyclophosphamide-based therapy may be favored when durable disease control is prioritized and toxicity is acceptable.
- Calcineurin inhibitor-based treatment requires attention to renal function and the possibility of less durable benefit after discontinuation.[15][22]
- Rituximab is an established first-line option for progressive primary membranous nephropathy and offers a non-calcineurin-inhibitor strategy.[19][21]

*Lesion-specific treatment expectations in nephrotic syndrome.[3][4][14][21][22]*

| Clinical phenotype | Preferred treatment direction | Key limitation or monitoring priority |
| --- | --- | --- |
| Childhood complicated steroid-dependent nephrotic syndrome | Rituximab as a steroid-sparing strategy that may allow calcineurin-inhibitor withdrawal.[3][4] | Follow relapse pattern and ability to reduce glucocorticoid and calcineurin-inhibitor exposure.[4] |
| Adult frequently relapsing or steroid-dependent minimal change disease | Consider rituximab to reduce relapses and glucocorticoid-sparing drug exposure.[14] | Evidence is predominantly from observational studies; response estimates should not be applied to resistant FSGS.[14] |
| Steroid-resistant disease after calcineurin-inhibitor failure, especially FSGS | Re-evaluate cause and avoid assuming benefit from rituximab.[4] | Rituximab response is limited in this phenotype.[4] |
| Progressive primary membranous nephropathy | Rituximab, cyclophosphamide plus glucocorticoids, or a calcineurin inhibitor-based regimen.[21] | Balance renal function, toxicity, and durability; calcineurin inhibitor advantages at 6 months were not sustained at 12 months in meta-analysis.[22] |
| Secondary membranous nephropathy | Treat hepatitis B or C, lupus, malignancy, or offending drug when identified.[7] | Do not classify as primary disease before secondary causes have been assessed.[7] |

## Refer early when biopsy, resistant disease, or systemic involvement will change therapy

Nephrology involvement is most valuable before irreversible treatment commitments are made.

Arrange expedited nephrology evaluation for adults with new nephrotic syndrome, declining eGFR, active urine sediment, suspected membranous nephropathy, suspected amyloid, recurrent thromboembolism, or steroid-resistant disease. Kidney biopsy and integrated pathology are often needed to distinguish potentially treatable primary disease from secondary, genetic, or infiltrative disease addressed in KDIGO glomerular-disease guidance.[6]

Escalate to hematology with suspected AL amyloidosis, particularly when renal protein loss coexists with elevated cardiac biomarkers or echocardiographic myocardial involvement. Cardiac staging thresholds include NT-proBNP 1,800 ng/L or greater, cardiac troponin T 0.025 ng/mL or greater, and difference in involved versus uninvolved free light chains of 180 mg/L or greater in the 2012 Mayo system.[12]

For children with frequent relapse, steroid dependence, calcineurin-inhibitor dependence, or steroid resistance, involve pediatric nephrology before repeated treatment cycles. Rituximab has demonstrated long-term utility in complicated steroid- and calcineurin-inhibitor-dependent childhood disease, but treatment selection must be linked to the response phenotype rather than nephrotic syndrome alone.[3][8]
- Repeat quantitative proteinuria and eGFR to judge trajectory rather than relying only on edema or dipstick results.
- Revisit the original diagnostic branch if proteinuria persists despite a regimen expected to induce remission; resistant disease may represent a missed secondary, genetic, or infiltrative process.[4][10][12]
- Use shared decision-making for prophylactic anticoagulation because evidence is limited and bleeding risk can outweigh uncertain benefit in lower-risk patients.[16]

*Findings that warrant accelerated specialty escalation.[3][6][12]*

| Finding | Specialty pathway | Reason |
| --- | --- | --- |
| Adult new-onset nephrotic syndrome with suspected primary glomerular disease | Nephrology and kidney biopsy planning | Histology guides diagnosis, prognosis, and treatment across glomerular diseases.[6] |
| Proteinuria with plasma-cell or cardiac amyloid features | Nephrology plus hematology | Renal and cardiac staging determine organ burden and prognosis in AL amyloidosis.[12] |
| Childhood steroid- and calcineurin-inhibitor-dependent disease | Pediatric nephrology | Rituximab can provide sustained remission and facilitate withdrawal of steroid and calcineurin-inhibitor exposure.[3][4] |
| Steroid-resistant FSGS phenotype after calcineurin-inhibitor failure | Nephrology with secondary/genetic re-evaluation | Rituximab benefit is limited in this setting, particularly in FSGS.[4] |

## References
1. Childhood nephrotic syndrome — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01051-6/abstract
2. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis — bmjopen.bmj.com — https://bmjopen.bmj.com/content/9/9/e030919
3. Rituximab for childhood-onset, complicated, frequently — www.thelancet.com — https://www.thelancet.com/pdfs/journals/lancet/PIIS0140673614605419.pdf
4. Rituximab therapy in nephrotic syndrome: implications for patients' management | Nature Reviews Nephrology — www.nature.com — https://www.nature.com/articles/nrneph.2012.289
5. Treatment of Progressive Membranous Glomerulopathy — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-116-6-438
6. Executive summary of the KDIGO 2021 Guideline for the ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253821005536
7. Primary glomerulonephritides — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0140673616002725
8. KDIGO 2025 Clinical Practice Guideline for the ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S008525382400797X
9. Focal segmental glomerular sclerosis in adults — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/0272638695901205
10. Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN | Nephrology Dialysis Transplantation | Oxford Academic — academic.oup.com — https://academic.oup.com/ndt/article/40/6/1091/7915083
11. Orphan Maintenance Assessment Report — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/orphan-maintenance-report/filspari-assessment-report-maintenance-orphan-designation-initial-authorisation_en.pdf
12. Amyloid consults do not have to be vexing — ashpublications.org — https://ashpublications.org/hematology/article/2023/1/407/506477/Amyloid-consults-do-not-have-to-be-vexing
13. Long-Term Survival (10 Years or More) in 30 Patients With ... — ashpublications.org — https://ashpublications.org/blood/article/93/3/1062/261194/Long-Term-Survival-10-Years-or-More-in-30-Patients
14. Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433659
15. Membranous nephropathy: When and how to treat - Kidney International — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(15)52489-7/fulltext
16. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2468024919315700
17. Current Therapies in Nephrotic Syndrome: HDAC inhibitors, an Emerging Therapy for Kidney Diseases — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2590262821000228
18. Glomerular Diseases Across Lifespan: Key Differences in ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0270929523001456
19. Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253826002267
20. Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0272638604008091
21. The outcomes of primary membranous nephropathy treated with cyclophosphamide are superior to calcineurin inhibitors in patients with renal vascular lesions: A multi-center retrospective cohort study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1567576924019015
22. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1568997216302713
23. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1567576921000126

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.